GH1 and Abdominal obesity: Among the general population, Bredella and colleagues demonstrated reductions in intrahepatic lipid among men with abdominal obesity, not selected for NAFLD, who received 6 months of recombinant human GH (rhGH) compared with those receiving placebo [89].